Singapore | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Singapore totalled $ 4.62 billion in 2023. Sales of commodity group 3002 from Singapore went up by 70% compared to 2022: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 1.9 billion (cumulative exports of commodity group 3002 from Singapore amounted $2.71 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 0.972% of total exports from Singapore (cumulative merchandise exports from Singapore totalled $ 475 billion in 2023). The share of commodity group 3002 in total exports from Singapore increased by 0.445 p.p. compared to 2022 (it was 0.527% in 2022 and cumulative exports from Singapore were equal to $ 514 billion).
Exports of commodity group 3002 amounted to 41% of total sales of group "" from Singapore in 2023 (the value of exports of commodity group from Singapore amounted to $11 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from Singapore increased by 14.2 p.p. compared to 2022 (it was 27% in 2022, and exports of commodity group from Singapore were $9.84 billion).
Where does Singapore export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Singapore in 2023:
- China with a share of 46% (2.15 billion US$)
- USA with a share of 17.9% (828 million US$)
- Switzerland with a share of 8.98% (415 million US$)
- Belgium with a share of 8.17% (378 million US$)
- Ireland with a share of 4.17% (193 million US$)
- Korea with a share of 2.98% (137 million US$)
- Germany with a share of 2.79% (129 million US$)
- Japan with a share of 1.69% (78 million US$)
- Netherlands with a share of 1.69% (78 million US$)
- Other Asia, nes with a share of 1.06% (49 million US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from Singapore in 2023 represented by the following main commodity groups:
- 0.196% (9.09 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to Singapore totalled $ 1.46 billion in 2023. Sales of commodity group 3002 to Singapore decreased by 27% in value terms compared to 2022. imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" decreased by $ 558 million (the value of imports of commodity group 3002 to Singapore was equal to $2.02 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 0.346% of total import flow to Singapore (in 2023, total imports to Singapore amounted to $ 422 billion). The share of commodity group 3002 in total imports to Singapore decreased by 0.078 p.p. compared to 2022 (it was 0.425% in 2022 and cumulative imports to Singapore were equal to $ 475 billion).
Imports of commodity group 3002 reached 33% of total imports of group "" to Singapore in 2023 (imports of commodity group to Singapore totalled $4.35 billion in 2023). The share of purchases of commodity group 3002 in imports of commodity group to Singapore went down by 5.39 p.p. compared to 2022 (it was 39% in 2022, and imports of commodity group to Singapore accounted for $5.18 billion).
Where does Singapore import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of Singapore in 2023:
- Ireland with a share of 20% (298 million US$)
- USA with a share of 18.6% (273 million US$)
- Spain with a share of 17.4% (255 million US$)
- Germany with a share of 9.03% (132 million US$)
- Belgium with a share of 6.94% (101 million US$)
- Switzerland with a share of 6.02% (88 million US$)
- France with a share of 4.09% (60 million US$)
- Sweden with a share of 3.05% (44 million US$)
- Netherlands with a share of 2.55% (37 million US$)
- Hungary with a share of 2.44% (35 million US$)
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to Singapore in 2023 represented by the following main commodity groups:
- 2.79% (40 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
